The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks. Thank you. Welcome to the Sandoz Q1 ...

Swiss generics and biosimilars major Sandoz (SIX: SDZ) has signed a global collaboration with Shanghai Henlius Biotech (HKEX: ...

Both Generics and Biosimilars segments underperformed, though the latter was notably weaker, missing consensus by 9%.

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to ...

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

Swiss generics and biosimilars major Sandoz (SIX: SDZ) today presented its net sales update for the first quarter of 2025.

LONDON, April 28 (Reuters) - The chief executive of generic drugmaker Sandoz (SDZ.S), opens new tab said a proposal by the CEOs of Novartis (NOVN.S), opens new tab and Sanofi (SASY.PA), opens new ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a ...

Richard Saynor, Chief Executive Officer of Sandoz, commented: “With Q1 sales in line with our expectations, we have now delivered fourteen consecutive quarters of top-line growth. This ...

Sandoz Group AG reported a 3% increase in net sales for the first quarter of 2025, driven by a strong performance in its biosimilars segment, which now constitutes 27% of total net sales.